46 results on '"Zukiwski, Alexander"'
Search Results
2. Development of a technique to detect the activated form of the progesterone receptor and correlation with clinical and histopathological characteristics of endometrioid adenocarcinoma of the uterine corpus
3. Exploring the in vitro potential of celecoxib derivative AR-12 as an effective antiviral compound against four dengue virus serotypes
4. A single-dose PK study of onapristone including the effect of food on absorption
5. Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma
6. Alteration in interactions between tumor-infiltrating lymphocytes and tumor cells in human melanomas after chemotherapy or immunotherapy
7. Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers
8. Regional biologic therapy: hepatic arterial infusion of recombinant human tumor necrosis factor in patients with liver metastases
9. AR-12 Inhibits Multiple Chaperones Concomitant With Stimulating Autophagosome Formation Collectively Preventing Virus Replication
10. The celecoxib derivatives AR-12 and AR-14 induce autophagy and clear prion-infected cells from prions
11. Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) alone or in combination with abiraterone (AA) in patients (pts) with castration-resistant prostate cancer (CRPC) incorporating plasma DNA analysis to define androgen receptor (AR) status.
12. Regression of hepatic metastases from gastrointestinal leiomyosarcoma after hepatic arterial chemo-embolization
13. AR-12 Inhibits Multiple Chaperones Concomitant With Stimulating Autophagosome Formation Collectively Preventing Virus Replication
14. Validation of a population pharmacokinetic (PPK) model for onapristone (ONA) in patients (pts) with cancer: Analysis of 2 clinical trials.
15. Multi-kinase inhibitors can associate with heat shock proteins through their NH2-termini by which they suppress chaperone function
16. AR-12 Inhibits Chaperone Proteins Preventing Virus Replication and the Accumulation of Toxic Misfolded Proteins
17. Abstract 4512: Onapristone in patients (pts) with progesterone receptor (PR)-expressing cancers: PK results from part 1 of a randomized, parallel-dose phase 1 study
18. Abstract 4523: Population pharmacokinetic (PPK) modeling of onapristone in patients (pts) with progesterone receptor (PR)-expressing cancers
19. Abstract 3471: Comparative assessment of in vitro activity and aactivated progesterone receptor (APR) biomarker predictivity for multiple antiprogestins
20. Onapristone (ONA) in progesterone receptor (PR)-expressing tumors: Efficacy and biomarker results of a dose-escalation phase 1 study.
21. Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) in patients (pts) with castration-resistant prostate cancer (CRPC): PK, safety and PR testing results from the dose escalation cohort.
22. Safety and pharmacokinetic (PK) results from phase 1 of an ongoing phase 1-2 study of onapristone (ONA) in patients (pts) with progesterone receptor (PR)-expressing cancers.
23. Phase 2 clinical study of onapristone (ONA) in patients (pts) with uterine endometrioid adenocarcinoma (EC) expressing the activated progesterone receptor (APRpos).
24. Abstract P5-02-13: Triple negative breast cancer, the impact of isotype-specific progesterone receptor antibodies on the diagnosis results
25. Abstract P6-08-19: Activated form of the estrogen receptor α (ER) in breast cancer (BC) and its correlation with prognosis
26. Abstract 5567: Impact of progesterone receptor (PR) isotype-specific immunohistochemistry (IHC) on the diagnosis of triple negative breast cancer (BC)
27. Abstract 1646: Synthesis of [11C]onapristone for clinical investigation
28. A randomized, parallel-dose phase 1 study of onapristone (ONA) in patients (pts) with progesterone receptor (PR)-expressing cancers.
29. A phase 1-2 study of the type I progesterone receptor (PR) antagonist onapristone (ONA) in patients (pts) with advanced castration-resistant prostate cancer (CRPC).
30. Clinical and pathologic correlation of the activated form of the estrogen receptor beta (ERβ) in breast cancer (BC).
31. Clinical and pathologic correlation of the activated form of the androgen receptor (AR) in breast cancer (BC).
32. Determination of the activated form of the progesterone receptor (PR) in endometrial cancer (EC).
33. Identification of the activated form of the estrogen receptor (ER) in breast cancer (BC).
34. A first-in-human phase I trial of AR-12, a PDK-1 inhibitor, in patients with advanced solid tumors.
35. Independent characterization by duel staining of progesterone receptor (PR) and estrogen receptor (ER) in breast cancer (BC).
36. Identification of the activated form of the progesterone receptor (PR) in breast cancer (BC).
37. Clinical and pathologic correlation of the activated form of the estrogen receptor (ER) in breast cancer (BC).
38. Abstract 1317: Antiprogestin drug development: in vitro validation of a potential clinical biomarker.
39. Combination Recombinant Interleukin-2, Recombinant Interferon-α, and 5-Fluorouracil for Treatment of Metastatic Renal Cell Carcinoma
40. Phase I Study of Tumor Necrosis Factor Plus Actinomycin D in Patients with Androgenindependent Prostate Cancer
41. Phase II Trial of Low Dose γ -Interferon in Metastatic Renal Cell Carcinoma
42. Phase I Study of Interleukin-2 Combined with Interferon-α and 5-Fluorouracil in Patients with Metastatic Renal Cell Cancer
43. Severe, symptomatic, dose-limiting hypophosphatemia induced by hepatic arterial infusion of recombinant tumor necrosis factor in patients with liver metastases
44. Increased incidence of hypersensitivity to iodine-containing radiographic contrast media after interleukin-2 administration
45. Indium-111-Labeled B72.3 Monoclonal Antibody in the Detection and Staging of Breast Cancer: A Phase I Study.
46. Recombinant α-Interferon Enhances Tumor Targeting of an Antimelanoma Monoclonal Antibody In Vivo.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.